Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
-
REGULATORY Govt, Pharma Leaders to Meet in August for Drafting of “Comprehensive Strategy”
July 13, 2015
-
ORGANIZATION “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
-
REGULATORY MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
-
BUSINESS Sawai Gearing Up to Revise 3-Year Biz Plan after New Generic Target
July 8, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
-
BUSINESS Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
-
REGULATORY NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
-
ORGANIZATION FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
July 2, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
-
REGULATORY Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
-
TRENDS 3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
REGULATORY Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
-
TRENDS “80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
REGULATORY LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
-
REGULATORY HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
-
REGULATORY Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
-
REGULATORY LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
-
REGULATORY 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…